Top papers in prostate cancer co-authored by OHSU faculty

Physician-scientists with the OHSU Knight Cancer Institute co-authored three of the 25 most important prostate cancer studies published this year, and one runner up, as judged by the Prostate Cancer...

Halting resurgent prostate cancers before they spread

Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...

Cracking the code of advanced prostate cancer

Understanding the tumor-specific alterations that are most important for prostate cancer aggressiveness and treatment decision-making will be the focus of a Marquam Hill...

A new line of attack on deadly prostate cancers

Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...

Outsmarting treatment-resistant prostate cancers

Aggressive prostate tumors can rapidly evolve to resist PARP inhibitors, but it may be possible to detect resistance early enough to counteract....

Widely used prostate cancer treatment may worsen risk of falls

Men with prostate cancer became more vulnerable to falls if they used androgen deprivation therapy, and the heightened risk of falling persisted for more than a year after ending therapy, a study...

Immunotherapy takes a new turn for life-threatening prostate cancer

At the recent European Society for Medical Oncology meeting, OHSU oncologist Julie Graff, M.D., presented the first evidence of meaningful clinical activity for PD-1 blockade in men with...

Digging in to questions that matter for men with prostate cancer

Cancer researchers presented more than 5,200 study findings at the American Society of Clinical Oncology meeting in June. Amid the hubbub, Knight Cancer Institute Deputy Director Tom Beer, M.D.,...